Enrico De Luca

Dr. Enrico De Luca

University of Florence - Department of Chemistry "Ugo Schiff"
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
Francesca MaestrelliFrancesca Maestrelli
Francesca Maestrelli
Patrizia RossiPatrizia Rossi
Patrizia Rossi
Paola PaoliPaola Paoli
Paola Paoli
ELEnrico De Luca
Enrico De Luca
Paola Angela MuraPaola Angela Mura
Paola Angela Mura

10 December 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Francesca MaestrelliFrancesca Maestrelli
Francesca Maestrelli
ELElisa Landucci
Elisa Landucci
ELEnrico De Luca
Enrico De Luca
GNGiulia Nerli
Giulia Nerli
Maria Camilla BergonziMaria Camilla Bergonzi
Maria Camilla Bergonzi
Cristina NativiCristina Nativi
Cristina Nativi
The transient receptor potential akyrin type-1 (TRPA1) is a non-selective cation channel playing a pivotal role in pain sensation and neurogenic inflammation. TRPA1 channels expressed in the central nervous system (CNS) have a critical role in the modulation of cortical spreading depression (CSD), which is a key pathophysiological basis of migraine pain. ADM_09 is a recently developed lipoic acid-based TRPA1 antagonist that is able to revert oxaliplatin-induced neuropathic pain and inflammatory trigeminal allodynia. In this context, aiming at developing drugs that are able to target TRPA1 channels in the CNS and promote an antioxidant effect, permeability across the blood–brain barrier (BBB) represents a central issue. Niosomes are nanovesicles that can be functionalized with specific ligands selectively recognized by transporters expressed on the BBB. In this work, the activity of ADM_09 on neocortex cultures was studied, and an efficient formulation to cross the BBB was developed with the aim of increasing the concentration of ADM_09 into the brain and selectively delivering it to the CNS rapidly after parenteral administration.

26 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Francesca MaestrelliFrancesca Maestrelli
Francesca Maestrelli
Marzia CirriMarzia Cirri
Marzia Cirri
ELEnrico De Luca
Enrico De Luca
DBDiletta Biagi
Diletta Biagi
Paola Angela MuraPaola Angela Mura
Paola Angela Mura
Flufenamic acid (FFA) is a non-steroidal anti-inflammatory drug characterised by a low solubility and problems of variable dissolution rate and bio-inequivalence. Different FFA batches, obtained by different suppliers, showed different powder characteristics (particle size, shape and surface properties) that may affect its dissolution behaviour from solid dosage forms. Aim of this work was the improvement of FFA solubility and dissolution rate by the use of cyclodextrins (CDs) and the obtainment of an effective tablet formulation by direct compression. Several CDs have been tested, both in solution and in solid state and several binary systems drug-CDs have been obtained with different techniques, with the scope to select the most effective system. Grinding technique with randomly methylated-β-cyclodextrin (RAMEB) was the only one that allowed the complete drug amorphization, together with the highest improvement in drug dissolution rate, and was then selected for tablets formulation. Conventional and immediate release tablets were obtained and fully characterised for technological properties. In both cases an improved and well reproducible drug dissolution performance was obtained, independently from the FFA supplier and thus no more affected by the differences observed between the original FFA crystalline samples.